Strs Ohio cut its stake in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 13.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,900 shares of the biotechnology company’s stock after selling 11,900 shares during the period. Strs Ohio owned 0.11% of Progenics Pharmaceuticals worth $697,000 as of its most recent filing with the SEC.
Other hedge funds have also added to or reduced their stakes in the company. Profund Advisors LLC bought a new position in Progenics Pharmaceuticals during the first quarter valued at about $128,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Progenics Pharmaceuticals during the fourth quarter worth $144,000. GSA Capital Partners LLP acquired a new stake in shares of Progenics Pharmaceuticals during the fourth quarter worth $163,000. Fox Run Management L.L.C. raised its stake in Progenics Pharmaceuticals by 64.1% in the first quarter. Fox Run Management L.L.C. now owns 19,532 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 7,632 shares in the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in Progenics Pharmaceuticals during the first quarter valued at $269,000. 92.66% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded up 3.14% during mid-day trading on Monday, reaching $6.90. The company’s stock had a trading volume of 1,281,918 shares. The stock has a market cap of $484.55 million, a P/E ratio of 71.13 and a beta of 3.37. The stock has a 50 day moving average of $6.98 and a 200-day moving average of $8.83. Progenics Pharmaceuticals Inc. has a one year low of $4.00 and a one year high of $11.72.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.07. The firm had revenue of $2.40 million for the quarter, compared to analyst estimates of $4.50 million. Progenics Pharmaceuticals had a return on equity of 7.50% and a net margin of 10.24%. The firm’s revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.18) EPS. On average, equities research analysts expect that Progenics Pharmaceuticals Inc. will post ($0.79) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/strs-ohio-reduces-stake-in-progenics-pharmaceuticals-inc-pgnx-updated-updated/862656.html.
A number of research analysts have issued reports on PGNX shares. TheStreet cut Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Friday, May 26th. Needham & Company LLC reiterated a “strong-buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Sunday, April 2nd. Zacks Investment Research cut Progenics Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $12.00 price target on shares of Progenics Pharmaceuticals in a report on Thursday, June 8th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $10.96.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.